• 3-Deazaadenosine Hydrochloride in m6A Assays

  2026-09-28

  3-Deazaadenosine hydrochloride is a selective S-adenosylhomocysteine hydrolase inhibitor for interrogating methylation-dependent biology. This guide connects SAHH inhibition with the IGF2BP1–TUBB4B liver-fibrosis model and translates the mechanism into better assay controls and interpretation.

• Difloxacin HCl: Mechanism, Uses, and Benchmarks

  2026-09-28

  Difloxacin HCl is a quinolone antimicrobial antibiotic described as an inhibitor of bacterial DNA gyrase and a reagent for antimicrobial susceptibility testing. Product information also reports multidrug resistance reversal in human neuroblastoma cells, a distinct research finding that should not be interpreted as evidence of clinical efficacy.

• Sulfo-Cy3 NHS Ester for Vascular Protein Assays

  2026-09-27

  Bring hydrophilic Cy3 labeling to vascular biology workflows that track proteins without adding an organic co-solvent. This practical guide connects the AIBP–LRP2–HDL findings to assay design, with starting conditions and controls for interpreting uptake and fluorescence.

• Wnt-C59: PORCN Inhibition for Wnt Research

  2026-09-26

  Wnt-C59 is a potent PORCN inhibitor for testing whether cells depend on PORCN-mediated Wnt secretion. Product information reports a 74 pM PORCN IC50 and preclinical activity in Wnt-responsive assays and tumor models, while the cited bone-regeneration study describes a distinct, Wnt-activating lithium mechanism.

• Caspofungin as a Translational Probe for Candida Cell Walls

  2026-09-25

  Explore how Caspofungin connects glucan-synthase biology with translational study design, using resistant Candida research to frame assay choices, benchmark interpretation, and the limits of preclinical evidence.

• EX 527: Testing SIRT1 Causality in Aging Bone

  2026-09-25

  EX 527 (SEN0014196) offers a selective way to test whether SIRT1 catalytic activity contributes to vascular and osteogenic phenotypes in aging-bone models. This article focuses on interpreting inhibition as a causal experiment—not as a simple reversal of SIRT1 activation—and on choosing readouts that make that distinction testable.

• Berberine, Tuft Cells, and Estrogen-Deficient Bone Loss

  2026-09-24

  A 2026 preclinical study links berberine’s protection against estrogen deficiency-associated bone resorption to a gut pathway involving butyrate, GPR41, and intestinal tuft cells. The findings point to gut-barrier restoration and Th17/Treg balance as mechanistic intermediates, while leaving human efficacy and optimal formulation or dosing unresolved.

• Plk1 Phosphorylation Restrains p31comet in MCC Disassembly

  2026-09-24

  The study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet, showing that phosphorylation at S102 suppresses p31comet–TRIP13-mediated release of Mad2 from mitotic checkpoint complexes. This regulatory step offers a mechanism for limiting premature checkpoint inactivation, although the evidence does not establish every aspect of its timing or operation in living cells.

• Fumagillin for Angiogenesis Research

  2026-09-23

  Use Fumagillin to probe MetAP-2-dependent endothelial responses, then connect proliferation readouts to functional angiogenesis assays. A published parasite screen offers a useful comparative benchmark—but not evidence that Fumagillin treats soft tunic syndrome in vivo.

• Masitinib (AB1010) Workflow Guide

  2026-09-23

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible KIT and PDGFR-focused kinase inhibitor for controlled cancer, mast-cell, and inflammatory research workflows. This guide explains formulation, assay setup, controls, and interpretation boundaries; it is not a substitute for clinical guidance or validation of aqueous and ethanol-based protocols.

• Masitinib (AB1010): Practical KIT/PDGFR Guide

  2026-09-22

  Masitinib (AB1010), SKU A2942, is a DMSO-compatible research inhibitor for studying KIT, PDGFRα, PDGFRβ, mast-cell responses, and selected KIT-mutant cell models. It is appropriate for controlled kinase and cell-based experiments, but not for aqueous or ethanol-based workflows, broad-spectrum kinase profiling, or clinical treatment decisions.

• Aclacinomycin A: Reliable Cytotoxicity Workflows

  2026-09-22

  This scenario-based guide shows how Aclacinomycin A (SKU A2601) can standardize cell-viability, apoptosis, and DNA-damage experiments. It combines product-specific IC50 cytotoxicity values with practical guidance on controls, solution stability, mechanism-aware interpretation, and vendor selection.

• Ibrexafungerp Activity Against Resistant Candida auris

  2026-09-21

  Wiederhold and colleagues combined susceptibility testing with a delayed-treatment murine model to examine ibrexafungerp against fluconazole-resistant Candida auris. The study found consistent in vitro activity and meaningful in vivo efficacy, including after therapy was postponed, supporting glucan synthase inhibition as a useful strategy for difficult invasive candidiasis.

• Doxorubicin A3966 for Reliable Cytotoxicity Assays

  2026-09-21

  This scenario-based guide explains how Doxorubicin SKU A3966 can improve interpretation of viability, proliferation, and cytotoxicity assays. It covers mechanism, exposure design, formulation, data comparison, cardiotoxicity modeling, and practical product-selection criteria.

• Caspofungin and the Next Logic of Candida Translation

  2026-09-20

  Caspofungin is more than a benchmark antifungal compound: it is a mechanistic probe for fungal cell wall vulnerability, resistance biology, assay design, and delayed-treatment translation. This article connects glucan synthase inhibition with decision-making strategies for researchers studying resistant Candida, including Candida auris.

8608 records 1/574 page Next 12345 下5页 Last page